These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 24562790)
21. Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology. Justulin LA; Acquaro C; Carvalho RF; Silva MD; Felisbino SL Int J Androl; 2010 Jun; 33(3):489-99. PubMed ID: 19490185 [TBL] [Abstract][Full Text] [Related]
22. Antifibrotic cardioprotection of berberine via downregulating myocardial IGF-1 receptor-regulated MMP-2/MMP-9 expression in diabetic rats. Li G; Xing W; Zhang M; Geng F; Yang H; Zhang H; Zhang X; Li J; Dong L; Gao F Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H802-H813. PubMed ID: 29957017 [TBL] [Abstract][Full Text] [Related]
23. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. London CA; Sekhon HS; Arora V; Stein DA; Iversen PL; Devi GR Cancer Gene Ther; 2003 Nov; 10(11):823-32. PubMed ID: 14605668 [TBL] [Abstract][Full Text] [Related]
24. Finasteride treatment alters MMP-2 and -9 gene expression and activity in the rat ventral prostate. Delella FK; Justulin LA; Felisbino SL Int J Androl; 2010 Feb; 33(1):e114-22. PubMed ID: 19508332 [TBL] [Abstract][Full Text] [Related]
25. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model. Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062 [TBL] [Abstract][Full Text] [Related]
26. Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model: A good alternative to study PCa progression and chemoprevention approaches. Kido LA; de Almeida Lamas C; Maróstica MR; Cagnon VHA Life Sci; 2019 Jan; 217():141-147. PubMed ID: 30528182 [TBL] [Abstract][Full Text] [Related]
27. Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment. Bruni-Cardoso A; Johnson LC; Vessella RL; Peterson TE; Lynch CC Mol Cancer Res; 2010 Apr; 8(4):459-70. PubMed ID: 20332212 [TBL] [Abstract][Full Text] [Related]
28. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action. Harper CE; Patel BB; Wang J; Eltoum IA; Lamartiniere CA Prostate; 2007 Oct; 67(14):1576-89. PubMed ID: 17705241 [TBL] [Abstract][Full Text] [Related]
29. Prostate hyperplasia caused by long-term obesity is characterized by high deposition of extracellular matrix and increased content of MMP-9 and VEGF. Silva SA; Gobbo MG; Pinto-Fochi ME; Rafacho A; Taboga SR; Almeida EA; Góes RM; Ribeiro DL Int J Exp Pathol; 2015 Feb; 96(1):21-30. PubMed ID: 25529509 [TBL] [Abstract][Full Text] [Related]
30. Differential expression of Low density lipoprotein Receptor-related Protein 1 (LRP-1) and matrix metalloproteinase-9 (MMP-9) in prostate gland: From normal to malignant lesions. Gilardoni MB; Remedi MM; Oviedo M; Dellavedova T; Sarría JP; Racca L; Dominguez M; Pellizas CG; Donadio AC Pathol Res Pract; 2017 Jan; 213(1):66-71. PubMed ID: 27931798 [TBL] [Abstract][Full Text] [Related]
31. Insulin-Like growth factor 1 related pathways and high-fat diet promotion of transgenic adenocarcinoma mouse prostate (TRAMP) cancer progression. Xu H; Jiang HW; Ding Q Actas Urol Esp; 2015 Apr; 39(3):161-8. PubMed ID: 25442907 [TBL] [Abstract][Full Text] [Related]
32. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Narayanan BA; Narayanan NK; Pittman B; Reddy BS Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007 [TBL] [Abstract][Full Text] [Related]
33. Differential tempol effects in prostatic cancer: angiogenesis and short- and long-term treatments. Santos FR; Rossetto IMU; Montico F; de Almeida Lamas C; Cagnon VHA J Mol Histol; 2024 Jun; 55(3):253-264. PubMed ID: 38551737 [TBL] [Abstract][Full Text] [Related]
34. Effect of 17beta-estradiol on apoptosis, IGF system components and gelatinases A and B in prostate cancer cells (PC-3). Kanagaraj P; Vijayababu MR; Ilangovan R; Senthilkumar K; Venkataraman P; Aruldhas MM; Arunakaran J Clin Chim Acta; 2007 Feb; 377(1-2):70-8. PubMed ID: 17083925 [TBL] [Abstract][Full Text] [Related]
35. β1 integrin- and JNK-dependent tumor growth upon hypofractionated radiation. Sayeed A; Lu H; Liu Q; Deming D; Duffy A; McCue P; Dicker AP; Davis RJ; Gabrilovich D; Rodeck U; Altieri DC; Languino LR Oncotarget; 2016 Aug; 7(33):52618-52630. PubMed ID: 27438371 [TBL] [Abstract][Full Text] [Related]
36. Nintedanib treatment delays prostate dorsolateral lobe cancer progression in the TRAMP model: contribution to the epithelial-stromal interaction balance. Nogueira Pangrazi E; da Silva RF; Kido LA; Montico F; Cagnon VHA Cell Biol Int; 2018 Feb; 42(2):153-168. PubMed ID: 28980742 [TBL] [Abstract][Full Text] [Related]
37. Reduction of Adipose Tissue Mass by the Angiogenesis Inhibitor ALS-L1023 from Melissa officinalis. Park BY; Lee H; Woo S; Yoon M; Kim J; Hong Y; Lee HS; Park EK; Hahm JC; Kim JW; Shin SS; Kim MY; Yoon M PLoS One; 2015; 10(11):e0141612. PubMed ID: 26599360 [TBL] [Abstract][Full Text] [Related]
38. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. Anzo M; Cobb LJ; Hwang DL; Mehta H; Said JW; Yakar S; LeRoith D; Cohen P Cancer Res; 2008 May; 68(9):3342-9. PubMed ID: 18451161 [TBL] [Abstract][Full Text] [Related]
39. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Azar DT Trans Am Ophthalmol Soc; 2006; 104():264-302. PubMed ID: 17471348 [TBL] [Abstract][Full Text] [Related]
40. The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor. Chen KT; Hour MJ; Tsai SC; Chung JG; Kuo SC; Lu CC; Chiu YJ; Chuang YH; Yang JS Int J Oncol; 2011 Sep; 39(3):611-9. PubMed ID: 21667022 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]